MASLD is regarded as a multifaceted pathological process encompassing aberrant lipid metabolism, insulin resistance, inflammation, gut microbiota imbalance, apoptosis, fibrosis, and cirrhosis. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.